Senior Management

Patrick Fourteau
Chief Executive Officer & President

Patrick Fourteau served as President and Chief Executive Officer of Shionogi US operations, from 2008 until 2010 following the acquisition of Sciele by Shionogi & Co., LTD. in 2008, Mr. Fourteau served as President, CEO, member of the board of directors of Sciele Pharma, Inc. from 2003 until 2008. Mr. Fourteau served as President of the US sales operations of inVentiv Health, Inc. from 2000 to 2002, President of various divisions of St. Jude Medical, Inc. from 1995 to 2000 and as an Executive of Eli Lilly and Company. He serves on the Board of Insys Therapeutics, Inc. Mr. Fourteau earned his B.A. and M.A. in Mathematics from the University of California, Berkeley and an MBA from Harvard University.

Harry H. Penner, Jr.
Executive Chairman, Founder

Mr. Penner has been a founder of seven other biotechnology companies, among which are Rib-X Pharmaceuticals (now Melinta Therapeutics), Prevention Pharmaceuticals, Affinimark Technologies, and Marinus Pharmaceuticals. From 1993 to 2001, he was President and Chief Executive Officer of Neurogen Corporation. Previously, he served as Executive Vice President of Novo Nordisk A/S and President of Novo Nordisk of North America, Inc. from 1988 to 1993. From 1985 to 1988, he was Executive Vice President and General Counsel of Novo Nordisk A/S. Mr. Penner, who also serves on the board of Celldex Therapeutics (CLDX), earned a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. from New York University.

Larry Dillaha, M.D.
Executive Vice President Operations

Prior to joining our company, Larry Dillaha, M.D. has served as the Chief Medical Officer at Insys Therapeutics, Inc. from April 2010 until May 2014. From 2006 until 2010, Dr. Dillaha served as EVP and Chief Medical Officer for Shionogi and Co., Ltd. (formerly Sciele Pharma, Inc.). While at Sciele, Dr. Dillaha oversaw the development and successful NDA approvals of 2 cardiology products, SULAR low dose, a LifeCycle extension of SULAR, and TRIGLIDE a fenofibrate. He has extensive experience in planning and overseeing clinical development programs. Dr. Dillaha served as Medical Director for Sanofi-Aventis. Dr. Dillaha earned his M.D. degree as well as a B.A. in Biology from the University of Tennessee.

Jeff Patrick, Pharm.D.
Chief Scientific Officer

Dr. Patrick has over fifteen years of scientific and medical experience in the pharmaceutical industry. Dr. Patrick has held a variety of leadership roles at Myogen, Gilead Sciences, Dyax and Mallinckrodt.

At Mallinckrodt, Jeff served as the Global Vice President, Medical Affairs, where he helped Mallinckrodt transition into a fully integrated specialty pharmaceutical company including assimilating a series of business acquisitions, including CNS Therapeutics, Cadence and Questcor.

Jeff holds a Doctorate of Pharmacy from the University of Tennessee Health Science Center, and completed a Specialty Residency in Ambulatory Care at the University of Tennessee Medical Center, Knoxville.

Michael Richardson
Chief Business Officer

Mr. Richardson has over twenty years of experience in pharmaceutical Marketing, Sales, Product Planning, Business Development and Licensing. Mr. Richardson had a variety of leadership roles at Grünenthal, Aton, Cephalon, Johnson & Johnson, and Merck. At Grünenthal, Michael served as Head of Commercial Affairs. At Aton Pharma, Michael served as Vice-President of Commercial Operations. At Cephalon, Michael served as Group Product Director resulting in the successful launch of multiple products. Michael holds a BA degree in Chemistry from West Virginia University and a MBA from the Fuqua School of Business at Duke University

Arthur Edwards
Special Advisor

Mr. Edwards comes to our company with over 35 years of experience working in the pharmaceutical and biopharmaceutical research & development areas. Prior to joining our company he was at Alexion Pharmaceuticals from 2004 to 2009, leaving with title of Executive Director of Global Regulatory Operations and US Regulatory Affairs.

In addition, Mr. Edwards worked for Purdue Pharma L.P. as the Director of Worldwide Regulatory Operations and prior to that Mr. Edwards was with Bayer Pharmaceuticals Inc. for 18 years starting in the CNS Medical Research group and advancing to the position of Head of Global Regulatory Submissions before leaving in 2003.

Mr. Edwards professional career also includes time at Serono Laboratories, Inc. USA, as a Senior Pharmaceutical Research Associate responsible for overseeing the monitoring of all Interferon [both natural & recombinant (r.DNA)] phase I & II clinical programs. Mr. Edwards also worked for the Procter & Gamble organization for 15 years where he started working in Toxicology advancing into Clinical Research, where he was a Medical Research Associate responsible for monitoring CNS and Anti-Infective clinical studies in North America and Mexico.

Mr. Edwards earned his Bachelor of Professional Science degree in Scientific Design and Financial Management from the State University of New York.

Cheryl Nash
Director Quality Assurance

Cheryl Nash serves as the Director of Quality Assurance at NHP since June 2013. Prior to joining our company, she served as Director Contractor QA from 2011 to May 2013 and Director QA Contract Manufacturing from 2009 to 2011 for Alexion Pharmaceuticals, Inc. While at Alexion, Cheryl directed the selection, qualification and oversight of contract manufacturers for biologic products and small molecules. She also oversaw the development and implementation of a PAI education program and inspection procedures that led to the successful PAI and approval for Alexion's first commercial product Soliris™.

Prior to serving as Director at Alexion, Ms. Nash served as Engineering Technical Specialist for Custom Manufacturing at GIBCO, Thermo Fisher Scientific, an international supplier of research materials. Ms. Nash earned her B.S. degree in Microbiology from The Ohio State University.